

101258

PTO/SB/81 (11-04)

Approved for use through 11/30/2005. OMB 0651-0035

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

**POWER OF ATTORNEY  
and  
CORRESPONDENCE ADDRESS  
INDICATION FORM**

|                             |  |
|-----------------------------|--|
| <b>Application Number</b>   | 10/596,853   |
| <b>Filing Date</b>          | July 11, 2008  |
| <b>First Named Inventor</b> | William Brown  |
| <b>Title</b>                | Diarylmethylidene Piperidine Derivatives,<br>Preparations Thereof And Uses Thereof |
| <b>Art Unit</b>             | To Be Determined   |
| <b>Examiner Name</b>        | To Be Determined   |
| <b>Attorney Docket No.</b>  | 133087.30401 (101258-1P US)  |

**I hereby revoke all previous powers of attorney given in the above-identified application.**

**I hereby appoint:**

☒ Practitioners associated with the Customer Number:

52286

**OR**

☐ Practitioner(s) named below:

| Name | Registration Number |
|------|---------------------|
|      |                     |
|      |                     |
|      |                     |
|      |                     |
|      |                     |

as my/our attorney(s) or agent(s) to prosecute the application identified above, and to transact all business in the United States Patent and Trademark Office connected therewith.

Please recognize or change the correspondence address for the above-identified application to:

☒ The address associated with the above-mentioned Customer Number

**OR**

☐ The address associated with Customer Number:

**OR**

☐ Firm or  
Individual Name

Address

City

State

ZIP

Country

Telephone

Fax

I am the:

☐ Applicant/Inventor.

☒ Assignee of record of the entire interest. See 37 CFR 3.71.

Statement under 37 CFR 3.73(b) is enclosed. (Form PTO/SB/96)

**SIGNATURE of Applicant or Assignee of Record**

Signature

Date

Name

Telephone

Title and Company

NOTE: Signatures of all the inventors or assignees of record of the entire interest or their representative(s) are required. Submit multiple forms if more than one signature is required, see below\*.

☐ \*Total of \_\_\_\_\_ forms are submitted.

This collection of information is required by 37 CFR 1.31 and 1.33. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.11 and 1.14. This collection is estimated to take 3 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

DOCKET NO.: 133087.30401 101258-1P US

PATENT

## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of: **William Brown et al.**Examiner: **To Be Determined**Serial No.: **10/596,853**Art Unit: **To Be Determined**Filing Date: **July 11, 2008**For: **Diarylmethylidene Piperidine Derivatives, Preparations Thereof And Uses Thereof**Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

Sir:

## STATEMENT UNDER 37 CFR 3.73(b)

Applicant or Patent Owner, **AstraZeneca AB.**, a company existing under the laws of **Sweden**, of Application No. **10/596,853** filed on **July 11, 2008** and entitled **Diarylmethylidene Piperidine Derivatives, Preparations Thereof And Uses Thereof**, states that it is:

- ☒ the assignee of the entire right, title, and interest; or  
☐ an assignee of less than the entire right, title, and interest.

The extent (by, percentage) of its ownership interest is **100%** in the patent application/patent identified above by virtue of either:


- ☒ A copy of the assignment from the inventor(s) of the patent application identified above is enclosed herewith.

The undersigned (whose title is supplied below) is authorized to act on behalf of the assignee.

Respectfully submitted,

ASTRAZENECA AB

Date: 12-1-08

By:   
Name: George A. Gilbert  
Title: Director, Patent Operations,  
Wilmington